ETF Holdings Breakdown of NRIX

NRIX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-10-17	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	22,993	USD 226,251
2025-10-17	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	50,556	USD 497,471
2025-10-17	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	50,556	USD 497,471
2025-10-17	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	41,968	USD 412,965 -5.2%
2025-10-17	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	950	USD 9,348 -5.2%
Total =		167,023	USD 1,643,506

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $28.87 Consensus Target Price from Brokerages

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price target […] - 2025-08-27 02:54:56

18,716 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by XTX Topco Ltd

XTX Topco Ltd purchased a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,716 shares of the company’s stock, valued at approximately $222,000. Other institutional investors and hedge funds have also […] - 2025-08-13 04:26:46

TD Asset Management Inc Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

TD Asset Management Inc increased its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 42,420 shares of the company’s stock after purchasing an additional 3,186 […] - 2025-08-05 04:34:52

HC Wainwright Lowers Nurix Therapeutics (NASDAQ:NRIX) Price Target to $34.00

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its target price cut by equities research analysts at HC Wainwright from $36.00 to $34.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 179.84% from the stock’s previous […] - 2025-07-16 04:26:52

Analysts Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $30.18

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12 month […] - 2025-07-08 03:10:44

Nurix: European Medicines Agency Grants Orphan Drug Designation To Bexobrutideg

(RTTNews) - Nurix Therapeutics (NRIX) announced that the European Medicines Agency has granted Orphan Drug Designation to bexobrutideg for the treatment of lymphoplasmacytic lymphoma. Bexobrutideg is an orally bioavailable, brain penetrant degrader of Brutons tyrosine kinase whic - 2025-07-07 08:41:27

Sumitomo Mitsui Trust Group Inc. Sells 33,252 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Sumitomo Mitsui Trust Group Inc. reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 4.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 755,970 shares of the company’s stock after selling 33,252 shares during the […] - 2025-07-04 05:13:03

Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.18

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 12-month target price […] - 2025-06-13 02:32:51

ProShare Advisors LLC Acquires 7,261 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 45.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,132 shares of the company’s stock after buying an additional 7,261 shares during the period. […] - 2025-05-28 05:09:01

Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Price Target at $30.44

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are currently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price […] - 2025-05-19 02:32:50

First Trust Advisors LP Acquires New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

First Trust Advisors LP bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 135,903 shares of the company’s stock, valued at approximately $2,560,000. First Trust Advisors LP owned approximately […] - 2025-05-05 06:24:57

Invesco Ltd. Sells 361,360 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Invesco Ltd. lessened its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,980 shares of the company’s stock after selling 361,360 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-02 05:06:53

Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Norges Bank acquired a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm acquired 318,800 shares of the company’s stock, valued at approximately $6,006,000. Other institutional investors also recently bought and sold shares of the company. NEOS Investment Management LLC purchased a new stake in […] - 2025-04-10 05:34:49

Vanguard Group Inc. Has $81.87 Million Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Vanguard Group Inc. boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.3% during the 4th quarter, HoldingsChannel reports. The fund owned 4,345,266 shares of the company’s stock after acquiring an additional 333,452 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Nurix Therapeutics worth $81,865,000 as of its most […] - 2025-04-10 04:44:59

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average 12-month price […] - 2025-03-27 04:38:49

US Bancorp DE Has $27,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

US Bancorp DE raised its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 144.7% in the 4th quarter, HoldingsChannel reports. The fund owned 1,424 shares of the company’s stock after acquiring an additional 842 shares during the period. US Bancorp DE’s holdings in Nurix Therapeutics were worth $27,000 at the end of the […] - 2025-03-20 06:28:53

Bank of New York Mellon Corp Purchases 15,639 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Bank of New York Mellon Corp lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 8.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 190,905 shares of the company’s stock after buying an additional 15,639 shares during the […] - 2025-03-20 06:28:53

Leerink Partners Initiates Coverage on Nurix Therapeutics (NASDAQ:NRIX)

Leerink Partners began coverage on shares of Nurix Therapeutics (NASDAQ:NRIX – Free Report) in a report published on Monday morning, MarketBeat Ratings reports. The firm issued a market perform rating and a $16.00 price target on the stock. Several other equities analysts also recently commented on the company. HC Wainwright increased their price target on […] - 2025-03-18 04:30:53

Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $31.81

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1-year price objective […] - 2025-03-05 04:53:07

Rhumbline Advisers Acquires 12,315 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Rhumbline Advisers raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 13.5% during the fourth quarter, Holdings Channel reports. The firm owned 103,233 shares of the company’s stock after buying an additional 12,315 shares during the quarter. Rhumbline Advisers’ holdings in Nurix Therapeutics were worth $1,945,000 at the end of […] - 2025-03-04 06:10:55

Nurix Therapeutics (NASDAQ:NRIX) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 to $17.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price target indicates a potential downside of 8.55% from […] - 2025-02-05 04:44:53

Back to Listing

Disclaimer